Kernel compositions of glyphosate-tolerant and corn rootworm-protected MON 88017 sweet corn and insect-protected MON 89034 sweet corn are equivalent to that of conventional sweet corn (Zea mays).

Monsanto Co. has developed two sweet corn hybrids, MON 88017 and MON 89034, that contain biotechnology-derived (biotech) traits designed to enhance sustainability and improve agronomic practices. MON 88017 confers benefits of glyphosate tolerance and protection against corn rootworm. MON 89034 provides protection against European corn borer and other lepidopteran insect pests. The purpose of this assessment was to compare the kernel compositions of MON 88017 and MON 89034 sweet corn with that of a conventional control that has a genetic background similar to the biotech sweet corn but does not express the biotechnology-derived traits. The sweet corn samples were grown at five replicated sites in the United States during the 2010 growing season and the conventional hybrid and 17 reference hybrids were grown concurrently to provide an estimate of natural variability for all assessed components. The compositional analysis included proximates, fibers, amino acids, sugars, vitamins, minerals, and selected metabolites. Results highlighted that MON 88017 and MON 89034 sweet corns were compositionally equivalent to the conventional control and that levels of the components essential to the desired properties of sweet corn, such as sugars and vitamins, were more affected by growing environment than the biotech traits. In summary, the benefits of biotech traits can be incorporated into sweet corn with no adverse effects on nutritional quality.

Measurement of Vitamin K1 in Commercial Canola Cultivars from Growing Locations in North and South America Using High-Performance Liquid Chromatography-Tandem Mass Spectrometry.

Plant oils, including canola oil, are considered to be major sources of vitamin K as the second most substantial contributor of vitamin K to the human diet. Green leafy vegetables are the largest source of vitamin K. However, the effects of environment and germplasm on vitamin K levels in harvested canola seed have not been extensively investigated. To better understand these relationships, harvested canola seed from a range of diverse cultivars grown in different geographical locations in North and South America was assessed for levels of vitamin K. The analytical method developed to perform this measurement was based on C30 reversed-phase HPLC that could distinguish the biologically active trans-vitamin K1 from the inactive cis-isomer. Results demonstrated that for the majority of the canola cultivars evaluated, those cultivated in the North American sites had higher average vitamin K1 levels than those cultivated in the South American sites. Not all of the cultivars exhibited differences in response to the environment, suggesting that individual cultivar genetics also played a role in the variability of vitamin K1 levels observed in canola seed. Results from this study suggest that cultivar and environmental effects influence vitamin K1 levels in canola seed and provide a context to assess compositional variability of new cultivars.

Consumption of stearidonic acid-rich oil in foods increases red blood cell eicosapentaenoic acid.

BACKGROUND: Consumption of soybean oil enriched with stearidonic acid was previously shown to increase eicosapentaenoic acid (EPA) in red blood cells (RBC). OBJECTIVE: This study was designed to evaluate the effect of stearidonic acid oil used as a food ingredient in baked products and beverages on the RBC fatty acid profile. DESIGN: This was a randomized, double-blind, controlled, parallel-arm study. PARTICIPANTS: Healthy men and women 21 to 65 years of age were included. INTERVENTION: Participants consumed either negative control (1.5 g/day high-oleic sunflower ethyl ester oil softgel capsules+foods containing 7 g/day high-oleic sunflower oil), positive control (1.5 g/day EPA oil ethyl ester softgel capsules+foods containing 7 g/day high-oleic sunflower oil), or active (1.5 g/day high-oleic sunflower ethyl ester oil softgel capsules+foods containing 7 g/day stearidonic acid soybean oil) for 12 weeks. MAIN OUTCOME MEASURES: RBC membrane fatty acid profile (at weeks 0, 2, 4, 6, 8, 10, and 12); fasting serum lipids (weeks -2, 0, 6, 10, and 12); and fasting plasma glucose and insulin (weeks -2, 0, 10, and 12) were assessed. STATISTICAL ANALYSES PERFORMED: A repeated measures analysis of covariance was used for continuous variables, and pair-wise comparisons between treatments were adjusted using a step-down Bonferroni method. Fisher's exact or χ(2) tests were used for categorical data. RESULTS: RBC %EPA throughout the 12-week study were significantly different between all groups. Means at 12 weeks were 0.50%±0.03%, 2.17%±0.21%, and 0.85%±0.05% for control, EPA, and stearidonic acid, respectively. Other efficacy outcome measures were not significantly different among treatment groups. CONCLUSIONS: Consumption of stearidonic acid-enriched soybean oil incorporated into common foods increased RBC %EPA in healthy men and women. Stearidonic acid soybean oil, a sustainable and accessible source of long-chain n-3, can effectively be used to increase EPA in RBC.

Stearidonic acid-enriched soybean oil increased the omega-3 index, an emerging cardiovascular risk marker.

A plant source of omega-3 fatty acid (FA) that can raise tissue eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA) is needed. A soybean oil (SBO) containing approximately 20% stearidonic acid [SDA; the delta-6 desaturase product of alpha-linolenic acid (ALA)] derived from genetically modified soybeans is under development. This study compared the effects of EPA to SDA-SBO on erythrocyte EPA+DHA levels (the omega-3 index). Overweight healthy volunteers (n=45) were randomized to SDA-SBO (24 ml/day providing approximately 3.7 g SDA) or to regular SBO (control group) without or with EPA ethyl esters (approximately 1 g/day) for 16 weeks. Serum lipids, blood pressure, heart rate, platelet function and safety laboratory tests were measured along with the omega-3 index. A per-protocol analysis was conducted on 33 subjects (11 per group). Compared to baseline, average omega-3 index levels increased 19.5% in the SDA group and 25.4% in the EPA group (p<0.05 for both, vs. control). DHA did not change in any group. Relative to EPA, SDA increased RBC EPA with about 17% efficiency. No other clinical endpoints were affected by SDA or EPA treatment (vs. control). In conclusion, SDA-enriched SBO significantly raised the omega-3 index. Since EPA supplementation has been shown to raise the omega-3 index and to lower risk for cardiac events, SDA-SBO may be a viable plant-based alternative for providing meaningful intakes of cardioprotective omega-3 FAs.